ATE310537T1 - Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen - Google Patents

Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Info

Publication number
ATE310537T1
ATE310537T1 AT03019610T AT03019610T ATE310537T1 AT E310537 T1 ATE310537 T1 AT E310537T1 AT 03019610 T AT03019610 T AT 03019610T AT 03019610 T AT03019610 T AT 03019610T AT E310537 T1 ATE310537 T1 AT E310537T1
Authority
AT
Austria
Prior art keywords
epoxy
treatment
combination therapy
cardiovascular diseases
converting enzyme
Prior art date
Application number
AT03019610T
Other languages
English (en)
Inventor
John C Alexander
Barbara Roniker
Subhash Desai
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of ATE310537T1 publication Critical patent/ATE310537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
AT03019610T 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen ATE310537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12297799P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
ATE310537T1 true ATE310537T1 (de) 2005-12-15

Family

ID=22406014

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03019610T ATE310537T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
AT00912174T ATE249242T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00912174T ATE249242T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Country Status (24)

Country Link
US (1) US20040077611A1 (de)
EP (2) EP1382351B8 (de)
JP (1) JP2002538172A (de)
KR (1) KR100580286B1 (de)
CN (1) CN1229141C (de)
AR (1) AR029155A1 (de)
AT (2) ATE310537T1 (de)
AU (2) AU778559B2 (de)
BR (1) BR0008781A (de)
CA (1) CA2364169A1 (de)
DE (2) DE60005159T2 (de)
DK (2) DK1165136T3 (de)
EA (1) EA004064B1 (de)
ES (2) ES2250803T3 (de)
HK (1) HK1042252B (de)
HU (1) HUP0200519A2 (de)
IL (2) IL145237A0 (de)
MX (1) MXPA01009035A (de)
NZ (1) NZ514205A (de)
PT (1) PT1165136E (de)
SI (1) SI1165136T1 (de)
TR (1) TR200102581T2 (de)
WO (1) WO2000051642A1 (de)
ZA (1) ZA200107779B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1580193A3 (de) * 1999-12-08 2010-06-23 Pharmacia Corporation Kristalline Form von Eplerenon
EP1505072A3 (de) * 1999-12-08 2006-06-21 Pharmacia Corporation Kristalline Form von Eplerenon mit verbesserter Lösegeschwindigkeit
CN1152886C (zh) * 1999-12-08 2004-06-09 法马西亚公司 表现出溶解速度加快的依匹乐酮晶形
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
AU2001255730A1 (en) * 2000-04-26 2001-11-07 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
EP3693460A1 (de) * 2012-07-27 2020-08-12 Ionis Pharmaceuticals, Inc. Modulation von mit dem reninangiotensinsystem (ras) assoziierten erkrankungen durch angiotensinogen
CN106267147A (zh) * 2015-06-10 2017-01-04 上药东英（江苏）药业有限公司 一种复方降压药物组合物
MX392014B (es) 2015-10-08 2025-03-21 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión de angiotensinógeno.
KR20230108728A (ko) 2020-11-18 2023-07-18 아이오니스 파마수티컬즈, 인코포레이티드 앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
CN1142793C (zh) * 1995-06-07 2004-03-24 G·D·瑟尔公司 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Also Published As

Publication number Publication date
EA200100951A1 (ru) 2002-04-25
TR200102581T2 (tr) 2002-04-22
EP1382351A1 (de) 2004-01-21
CN1229141C (zh) 2005-11-30
CA2364169A1 (en) 2000-09-08
DE60005159T2 (de) 2004-07-22
AU2005201045A1 (en) 2005-04-07
HK1061200A1 (en) 2004-09-10
EP1382351B8 (de) 2006-03-08
ES2250803T3 (es) 2006-04-16
US20040077611A1 (en) 2004-04-22
EP1165136B1 (de) 2003-09-10
DK1382351T3 (da) 2006-01-23
BR0008781A (pt) 2002-07-02
EP1382351B1 (de) 2005-11-23
HK1042252B (en) 2004-04-23
PT1165136E (pt) 2004-02-27
AU3394500A (en) 2000-09-21
DK1165136T3 (da) 2004-01-12
DE60024335T2 (de) 2006-08-03
HK1042252A1 (en) 2002-08-09
KR20010108319A (ko) 2001-12-07
SI1165136T1 (en) 2004-02-29
WO2000051642A1 (en) 2000-09-08
HUP0200519A2 (hu) 2002-07-29
JP2002538172A (ja) 2002-11-12
DE60024335D1 (de) 2005-12-29
KR100580286B1 (ko) 2006-05-16
ES2206204T3 (es) 2004-05-16
AU778559B2 (en) 2004-12-09
CN1372475A (zh) 2002-10-02
EP1165136A1 (de) 2002-01-02
ZA200107779B (en) 2002-12-20
NZ514205A (en) 2004-07-30
MXPA01009035A (es) 2004-08-12
IL145237A (en) 2006-08-01
AR029155A1 (es) 2003-06-18
DE60005159D1 (de) 2003-10-16
ATE249242T1 (de) 2003-09-15
IL145237A0 (en) 2002-06-30
EA004064B1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE381347T1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60042451D1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE369851T1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE350364T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
DE60024335D1 (de) Kombinationstherapie von Angiotensin-konvertierendem Enzymhemmer und Epoxy-steroidalem Aldosteron Antagonist zur Behandlung von kardiovaskulären Erkrankungen
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
AU9546501A (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
EP1416957A4 (de) Behandlung von immunerkrankungen und b-zellen-erkrankungen
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60018591D1 (de) Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE236653T1 (de) Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen
DE60036723D1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
EP1330271A4 (de) Verwendung von transkriptionsfaktoren zur behandlung von entzündungen und anderen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1382351

Country of ref document: EP

REN Ceased due to non-payment of the annual fee